Risk factors for checkpoint inhibitor pneumonitis in lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
BackgroundImmune checkpoint inhibitors (ICIs) significantly improve survival in lung cancer patients. However, checkpoint inhibitor pneumonitis (CIP) remains a critical safety concern. This meta-analysis systematically evaluates demographic, clinical, and laboratory risk factors associated with CIP...
Saved in:
| Main Authors: | Xiaoqing Zhou, Yingnan Xu, Yuanyuan Ying, Ruilin Chen, Zhen Wang, Xin Lv |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1607170/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Does Pre-Existing Chronic Obstructive Pulmonary Disease Increase the Risk of Checkpoint Inhibitor Pneumonitis in Advanced/Metastatic Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors?
by: David Spillane, et al.
Published: (2025-04-01) -
A Systematic Review of Pneumonitis Following Treatment with Immune Checkpoint Inhibitors and Radiotherapy
by: Melina Yerolatsite, et al.
Published: (2025-04-01) -
Managing Immune Checkpoint Inhibitor Pneumonitis in the ICU
by: Kristina Montemayor, MD, MHS, et al.
Published: (2025-03-01) -
Cytokine profile of bronchoalveolar lavage in patients with and without checkpoint inhibitor pneumonitis
by: Michelle Ploch, et al.
Published: (2025-01-01) -
Clinical features of immune checkpoint inhibitor-related pneumonitis in older patients with lung cancer receiving immune checkpoint inhibitors-based therapy: a retrospective study
by: Jiafan Liu, et al.
Published: (2025-04-01)